MX383245B - Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. - Google Patents
Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.Info
- Publication number
- MX383245B MX383245B MX2017007148A MX2017007148A MX383245B MX 383245 B MX383245 B MX 383245B MX 2017007148 A MX2017007148 A MX 2017007148A MX 2017007148 A MX2017007148 A MX 2017007148A MX 383245 B MX383245 B MX 383245B
- Authority
- MX
- Mexico
- Prior art keywords
- hyperammonemia
- diseases associated
- treat diseases
- modified bacteria
- bacteria
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 2
- 206010020575 Hyperammonaemia Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/10—Citrulline; Arginine; Ornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01001—Amino-acid N-acetyltransferase (2.3.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087854P | 2014-12-05 | 2014-12-05 | |
| US201562103513P | 2015-01-14 | 2015-01-14 | |
| US201562150508P | 2015-04-21 | 2015-04-21 | |
| US201562173706P | 2015-06-10 | 2015-06-10 | |
| US201562173710P | 2015-06-10 | 2015-06-10 | |
| US201562183935P | 2015-06-24 | 2015-06-24 | |
| US201562184811P | 2015-06-25 | 2015-06-25 | |
| US201562256039P | 2015-11-16 | 2015-11-16 | |
| US201562256041P | 2015-11-16 | 2015-11-16 | |
| US201562263329P | 2015-12-04 | 2015-12-04 | |
| PCT/US2015/064140 WO2016090343A1 (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007148A MX2017007148A (es) | 2017-10-11 |
| MX383245B true MX383245B (es) | 2025-03-13 |
Family
ID=55022714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007148A MX383245B (es) | 2014-12-05 | 2015-12-04 | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. |
| MX2021006581A MX2021006581A (es) | 2014-12-05 | 2017-06-05 | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006581A MX2021006581A (es) | 2014-12-05 | 2017-06-05 | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9487764B2 (enExample) |
| JP (1) | JP6768689B2 (enExample) |
| KR (1) | KR102493174B1 (enExample) |
| AU (1) | AU2015357549B2 (enExample) |
| BR (1) | BR112017011923A2 (enExample) |
| CA (1) | CA2969724A1 (enExample) |
| IL (2) | IL252627B (enExample) |
| MX (2) | MX383245B (enExample) |
| SG (2) | SG10202010444UA (enExample) |
| WO (1) | WO2016090343A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US10610546B2 (en) | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| AU2015357549B2 (en) * | 2014-12-05 | 2022-03-24 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US20160206666A1 (en) * | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| US11291693B2 (en) * | 2015-06-25 | 2022-04-05 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| EP3402498A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| WO2017184565A1 (en) | 2016-04-20 | 2017-10-26 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for nucleic acid expression and protein secretion in bacteroides |
| AU2017376780B2 (en) | 2016-12-15 | 2024-12-12 | Novome Biotechnologies, Inc. | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
| MX2019008196A (es) | 2017-01-06 | 2019-12-16 | Synlogic Operating Co Inc | Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales. |
| JP2020516318A (ja) * | 2017-04-17 | 2020-06-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 操作された共生細菌及び使用方法 |
| WO2018237198A1 (en) | 2017-06-21 | 2018-12-27 | Synlogic Operating Company, Inc. | Bacteria for the treatment of disorders |
| US20200113950A1 (en) * | 2017-06-30 | 2020-04-16 | The Rockefeller University | Human microbiota derived N-acyl amides for the treatment of human disease |
| KR20200064980A (ko) | 2017-07-12 | 2020-06-08 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물 |
| EP3703705B1 (en) | 2017-11-03 | 2024-05-15 | DSM Nutritional Products, LLC | Glucose-containing glycan preparations for use in the treatment of hyperammonaemia |
| AU2018379996A1 (en) * | 2017-12-05 | 2020-06-25 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
| CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| JP2021525760A (ja) | 2018-06-02 | 2021-09-27 | シンロジック オペレーティング カンパニー インコーポレイテッド | 肝疾患を処置するように操作された細菌 |
| US12410206B2 (en) | 2018-08-21 | 2025-09-09 | Dsm Nutritional Products, Llc | Oligosaccharide compositions and methods of use thereof for reducing ammonia levels |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| JP2022506635A (ja) | 2018-11-08 | 2022-01-17 | カレイド・バイオサイエンシズ・インコーポレイテッド | オリゴ糖組成物およびその使用方法 |
| EP3963046A1 (en) | 2019-04-29 | 2022-03-09 | Synlogic Operating Company, Inc. | Enumeration of genetically engineered microorganisms by live cell counting techniques |
| WO2020237246A1 (en) * | 2019-05-23 | 2020-11-26 | University Of Maryland, Baltimore | Live attenuated non-transmissible vaccines |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| CN115279888B (zh) | 2019-11-29 | 2024-04-02 | 株式会社Jinis | 具有降低血氨数值效能的菌株及包含其的用于保护神经细胞的组合物 |
| CN112924607A (zh) * | 2019-12-05 | 2021-06-08 | 湖北远大生物技术有限公司 | 一种同时检测酶促反应液中α-酮戊二酸和L-谷氨酸的方法 |
| EP4121525A1 (en) | 2020-03-20 | 2023-01-25 | Synlogic Operating Company, Inc. | Microorganisms engineered to reduce hyperphenylalaninemia |
| WO2022120028A2 (en) | 2020-12-02 | 2022-06-09 | Synlogic Operating Company, Inc. | Engineered microorganisms |
| EP4436407A1 (en) | 2021-11-22 | 2024-10-02 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
| KR102853096B1 (ko) * | 2022-03-18 | 2025-09-02 | 씨제이제일제당 주식회사 | 카르바모일 인산 합성효소의 활성이 약화된 l-아미노산을 생산하는 미생물 및 이를 이용한 l-아미노산 생산 방법 |
| CN115960807A (zh) * | 2022-11-29 | 2023-04-14 | 深圳先进技术研究院 | 一种厌氧高产l-精氨酸工程菌及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| CA2353800A1 (en) | 1998-12-02 | 2000-06-08 | Trustees Of Boston University | Gene networks for control of gene expression |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| JP4682454B2 (ja) * | 2000-06-28 | 2011-05-11 | 味の素株式会社 | 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法 |
| DE10101793A1 (de) * | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| ES2340405T3 (es) * | 2004-09-28 | 2010-06-02 | Kyowa Hakko Bio Co., Ltd. | Metodo para producir l-arginina, l-ornitina o l-citrulina. |
| AU2015357549B2 (en) * | 2014-12-05 | 2022-03-24 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
-
2015
- 2015-12-04 AU AU2015357549A patent/AU2015357549B2/en not_active Ceased
- 2015-12-04 KR KR1020177018338A patent/KR102493174B1/ko active Active
- 2015-12-04 WO PCT/US2015/064140 patent/WO2016090343A1/en not_active Ceased
- 2015-12-04 MX MX2017007148A patent/MX383245B/es unknown
- 2015-12-04 JP JP2017548375A patent/JP6768689B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,333 patent/US9487764B2/en active Active
- 2015-12-04 SG SG10202010444UA patent/SG10202010444UA/en unknown
- 2015-12-04 BR BR112017011923A patent/BR112017011923A2/pt not_active Application Discontinuation
- 2015-12-04 CA CA2969724A patent/CA2969724A1/en not_active Abandoned
- 2015-12-04 SG SG11201704543XA patent/SG11201704543XA/en unknown
-
2017
- 2017-06-01 IL IL252627A patent/IL252627B/en active IP Right Grant
- 2017-06-05 MX MX2021006581A patent/MX2021006581A/es unknown
-
2020
- 2020-10-19 IL IL278150A patent/IL278150A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021006581A (es) | 2021-07-15 |
| KR20170097078A (ko) | 2017-08-25 |
| AU2015357549A1 (en) | 2017-06-29 |
| KR102493174B1 (ko) | 2023-01-27 |
| US20160177274A1 (en) | 2016-06-23 |
| SG11201704543XA (en) | 2017-07-28 |
| WO2016090343A1 (en) | 2016-06-09 |
| AU2015357549B2 (en) | 2022-03-24 |
| BR112017011923A2 (pt) | 2018-02-27 |
| JP2018504919A (ja) | 2018-02-22 |
| MX2017007148A (es) | 2017-10-11 |
| SG10202010444UA (en) | 2020-11-27 |
| IL278150A (en) | 2020-11-30 |
| JP6768689B2 (ja) | 2020-10-14 |
| WO2016090343A9 (en) | 2016-09-09 |
| US9487764B2 (en) | 2016-11-08 |
| IL252627A0 (en) | 2017-07-31 |
| IL252627B (en) | 2020-11-30 |
| CA2969724A1 (en) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383245B (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| PH12019502724A1 (en) | Compositions for modulating c9orf72 expression | |
| IL271085A (en) | Bacteria for the treatment of disorders | |
| BR112017006664A2 (pt) | terapias de combinação | |
| MX2020011749A (es) | Composiciones y metodos para modular la expresion de pkk. | |
| WO2016200614A3 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| BR112017003111A2 (pt) | composições e métodos para o tratamento de distúrbios neurológicos | |
| NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
| WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| WO2017139697A8 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| MX2017005064A (es) | Metodos para tratar afecciones oculares. | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| TW201613949A (en) | Targeting microRNAs for metabolic disorders | |
| MX395492B (es) | Usos terapeuticos de l-4 cloroquinurenina. | |
| EP3595688A4 (en) | GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| MX2016010967A (es) | Nuevas composiciones para tratar lesiones neuronales mecanicas. | |
| EA201592012A1 (ru) | Применение флагеллина для улучшенной химиотерапии | |
| TH1501007678A (th) | สารละลายไฮโดรเจนเพอร์ออกไซด์ที่ใช้สำหรับฆ่าเชื้อแบคทีเรียและวิธีการผลิตนั้น รวมทั้งวิธีการฆ่าเชื้อแบคทีเรียโดยใช้สารดัวกล่าว |